STAAR Surgical Reports 111% Revenue Growth to $93.5 Million in Latest Quarter

STAAR Surgical Company reported significant financial improvements in its latest quarterly results, with net sales reaching $93.5 million for the three months ended July 3, 2026, a substantial increase of 111% compared to $44.3 million in the same period last year. For the first half of 2026, the company generated $187.1 million in revenue, up 115% from $86.9 million in the prior year. The growth was primarily driven by strong sales in China, where net sales surged to $52.3 million from $5.3 million in the previous year. Gross profit also saw a notable increase, rising to $69.7 million, with a gross margin of 74.5%, up from 74.0% in the prior year.

The company’s operational metrics reflected a positive trend, with selling, general, and administrative expenses decreasing to $59.6 million from $62.8 million year-over-year. This reduction was attributed to the absence of restructuring charges that had impacted the previous year’s results. However, the current quarter included increased costs related to the implementation of an enterprise resource planning (ERP) system and severance expenses due to headcount reductions in Global Marketing. The company reported a net income of $8.1 million, or $0.16 per diluted share, a significant turnaround from a net loss of $16.8 million, or $(0.34) per share, in the same quarter last year.

In terms of strategic developments, STAAR Surgical has been focusing on expanding its market presence, particularly in Asia. The company has implemented consignment agreements with distributors in China to mitigate potential financial exposure from tariffs, which has contributed to the increase in sales. The company is also in the process of enhancing its operational capabilities through the ERP system, which is expected to streamline processes and improve efficiency in the long term.

As of July 3, 2026, STAAR Surgical's total assets increased to $475.2 million from $451.7 million at the beginning of the year, with current assets rising to $342.4 million. The company’s cash and cash equivalents stood at $148.6 million, down slightly from $153.2 million at the start of the year. The company’s current liabilities also increased to $73.4 million, reflecting ongoing investments in growth and operational improvements. The company’s employee headcount has been adjusted as part of its restructuring efforts, which are aimed at aligning its workforce with strategic goals.

Looking ahead, STAAR Surgical anticipates continued growth driven by increased demand for its Implantable Collamer® Lenses (ICLs) and the scaling of production capabilities in Switzerland. The company expects to fully supply its EVO and EVO+ ICL lenses for the Chinese market from Switzerland by the end of 2026, which should further enhance its gross margins. However, the company remains cautious about potential impacts from tariffs and global economic conditions, which could affect future performance.